Abstract: The present invention relates to Regentide-012 and Regentide-013 and, more specifically, to a use of Regentide-012 and Regentide-013 for improving skin conditions. Regentide-012 and Regentide-013 according to the present invention is free of cytotoxicity and have remarkable effects of skin aging reduction, skin regeneration, skin elasticity improvement, skin wrinkle prevention, skin wrinkle reduction, and skin wound recovery and as such, can be variously utilized in the pharmaceutical, medicinal, cosmetic, and food fields.

Abstract: The present invention relates to regentide-034 and, more specifically, to a use of regentide-034 for improving the condition of the skin. Regentide-034 according to the present invention is noncytotoxic and has remarkable effects of skin aging alleviation, skin regeneration, skin elasticity improvement, skin wrinkle prevention, skin wrinkle reduction and skin wound regeneration, and thus can be variously used in the fields of pharmacology, medicine, cosmetics, and food.

Abstract: The present invention relates to Regentide-034 and Regentide-041 and, more specifically, to a use of a mixture of Regentide-034 and Regentide-041 for improving skin conditions. A mixture of Regentide-034 and Regentide-041 according to the present invention is free of cytotoxicity and has remarkable effects of promoting cell proliferation and collagen synthesis, inhibiting elastase activity, and suppressing ultraviolet light-induced cell death and as such, can be variously utilized in the pharmaceutical, medicinal, cosmetic, and food fields.

Abstract: The present invention relates to Regentide-041 and, more specifically, to a use of Regentide-041 for improving skin conditions. Regentide-041 according to the present invention is free of cytotoxicity and has remarkable effects of skin aging reduction, skin regeneration, skin elasticity improvement, skin wrinkle prevention, skin wrinkle reduction, and skin wound recovery and as such, can be variously utilized in the pharmaceutical, medicinal, cosmetic, and food fields.

Abstract: The present invention relates to a pharmaceutical composition for promoting the healing of wounds, containing lysophosphatidic acid and an adenylyl cyclase inhibitor as active ingredients, and more particularly, to a pharmaceutical composition which contains an adenylyl cyclase inhibitor and which promotes the healing of wounds in senescent cells or aged persons having physiological characteristics different than those of young cells or young persons. In addition, the present invention relates to a method for promoting the healing of wounds involving treating a wounded person with an effective dose of the lysophosphatidic acid and adenylyl cyclase inhibitor.

Abstract: The present invention relates to the molecular mechanism inducing cell proliferation in aged human fibroblasts by inhibiting AMPK using LPA and AC inhibitor. Particularly, the present invention relates to a composition comprising LPA and ACI as active ingredients and the invention proves with the said composition that LPA and ACI regulate different phosphorylation of AMPK? and thus inactivate p53 and induce senescent cell proliferation. This results support the fact that AMPK signal transduction plays an important role in cell proliferation of senescent cells.